Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000466484 | SCV000547945 | uncertain significance | RASopathy | 2024-05-08 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 119 of the SHOC2 protein (p.Ile119Val). This variant is present in population databases (rs147068827, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with SHOC2-related conditions. ClinVar contains an entry for this variant (Variation ID: 181527). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SHOC2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV000763645 | SCV000894520 | uncertain significance | Noonan syndrome-like disorder with loose anagen hair 1 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001813417 | SCV002060868 | uncertain significance | Noonan syndrome and Noonan-related syndrome | 2016-12-12 | criteria provided, single submitter | clinical testing | |
Ce |
RCV002262761 | SCV002544461 | likely benign | not provided | 2023-03-01 | criteria provided, single submitter | clinical testing | SHOC2: BP4, BS2 |
Ambry Genetics | RCV002336368 | SCV002618819 | uncertain significance | Cardiovascular phenotype | 2024-12-10 | criteria provided, single submitter | clinical testing | The c.355A>G (p.I119V) alteration is located in exon 2 (coding exon 1) of the SHOC2 gene. This alteration results from a A to G substitution at nucleotide position 355, causing the isoleucine (I) at amino acid position 119 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV002262761 | SCV005412235 | uncertain significance | not provided | 2024-04-24 | criteria provided, single submitter | clinical testing |